Stock Ratings / Health Care / PMI / dividends

NSPR (32) RVP (31) MODD (33) PLRZ (34) ⌘ Pro Terminal →

Picard Medical Inc. (PMI) Dividend Safety Gauge & 10-Year DRIP Compounder

$8.35 +2.96% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.38

Picard Medical Inc. (PMI) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $20.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PMI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PMI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Picard Medical Inc. (NYSE: PMI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $8.35 (+2.96% 1D, market cap $20.5M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PMI compare to NSPR and RVP in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), PMI carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NSPR (InspireMD Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $20.9M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, PMI leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PMI?

▼

Per PMI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002030617), Picard Medical Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $22.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.38 (+0.34%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PMI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY PMI SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($574.8K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$15.33-31.6% Next Q

Q2 (-2Q)

Grade C-$10.48-34.8% Next Q

Q3 (-1Q)

Grade C-$6.83+22.3% Next Q

Current

Grade D$8.35-5.6% Hist 90D α

Trajectory: C (56) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PMI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PMI currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.34) and Max Pain ($8.77) forces dealer call-delta covering toward $218.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PMI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PMI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PMI)

✓Walkthrough of PMI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PMI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.56%▼ DESCENDING CHANNEL

2026-11-03O $8.11H $8.35L $8.11C $8.35VOL 56.4K

RES: $18.01SUP: $0.27SMA50: $7.34SMA200: $26.77

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PMI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PMI Butterfly Map → + Track PMI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PMI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PMI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PMI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PMI)

Health Care Rank #294 of 1016 ⚔️ NSPR vs PMI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PMI vs. NSPR, RVP, MODD, PLRZ)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Picard Medical Inc. (PMI) ranks #294 by composite RQD confidence (48/100, grade D) and #830 by equity capitalization ($20.5M). Within this direct 5-issuer industry benchmark cohort, PMI leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PMI ACTIVE Picard Medical Inc.	D	48/100	—	—	—	+2.96%	$20.5M	Benchmark Subject
NSPR InspireMD Inc.	E	32/100	—	29.5%	-35.0%	-0.31%	$20.9M	/nspr-vs-pmi →
RVP Retractable Technologies Inc.	E	31/100	—	0.1%	-23.3%	-1.96%	$16.9M	/rvp-vs-pmi →
MODD Modular Medical Inc.	E	33/100	—	—	-35.0%	0.00%	$16.3M	/modd-vs-pmi →
PLRZ Polyrizon Ltd.	E	34/100	—	—	-25.1%	+19.40%	$26.1M	/plrz-vs-pmi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002030617

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Picard Medical Inc. (PMI) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, PMI closed FY2025 with $22.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$22.5M	—

3. PMI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PMI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PMI compare to NSPR and RVP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PMI?

Where is PMI trading relative to its 50-day, 200-day, and 52-week technical levels?

PMI last traded at $8.35 (+2.96% on volume of 56,350 shares), positioning the stock +13.76% above its 50-day simple moving average ($7.34) and -68.81% below its 200-day simple moving average ($26.77). Across its 52-week range of $2.65 to $208.00, PMI sits at the 2.8% percentile with a 14-day RSI of 50.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.31 to $9.39).

PMI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does PMI pay a dividend and is it safe?

Picard Medical Inc. (PMI) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: PMI RQD Cockpit PMI 12M Forecast PMI Earnings & Move PMI Dividends & DRIP PMI Insiders & 13F PMI Whale Options PMI Profit Sankey PMI News & Why

ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PMI — Picard Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:19:49Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PMI carries a score of 48 out of 100, a letter grade of D, and the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 10/20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 7/20 (institutional accumulation and options positioning); Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 9/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the cash-engine pillar is the weakest signal: the source data reports zero ROIC and zero FCF yield, so the rating reflects no demonstrated cash generation at present. The balance-sheet pillar is the strongest, with an Altman Z of 2.5 and a Piotroski F of 6/9, which together describe a financial position that the rating treats as relatively sturdier than its earnings profile. Flow and insider pillars are mid-to-low, indicating limited evidence of conviction from institutional or insider participants. Macro fit at a beta of 1.0 means the stock is assessed as moving in line with the broader market, without a defensive or amplified profile. The verdict implies that, on this framework, the stock's upside case rests on catalysts rather than on current earnings, and that a distribution-warning label signals elevated risk of downside. This analysis is educational and does not constitute personalized financial advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$7.5M	N/A

Per the SEC financials, FY 2025 reports zero revenue, zero operating income, and zero net income, with cash of $7.5M and debt not reported. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity of 0.5. The balance-sheet pillar is the rating's strongest component, while the absence of reported profitability and cash flow is the principal weakness.

Open Questions

What is the company's revenue history and business model, given that FY 2025 reports zero revenue and zero net income?
What was the nature and scope of the 1-for-50 reverse split referenced in market coverage, and how did it affect share count?
What are the substance and status of the claims referenced in the Johnson Fistel investigation notice?
What is the company's debt position, given that debt is reported as N/A while Debt/Equity is cited at 0.5?
What is the source of the cash runway behind the $7.5M cash balance, and what is the implied burn rate?

PMI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Picard Medical Inc. (PMI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PMI Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 19h ago

Picard Medical (PMI) Stock Forecast & Analyst Ratings

Moomoo report covering Picard Medical Inc. (PMI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 22h ago

Why Is Picard Medical (NYSEAMERICAN:PMI) Down 10.80% at an Overbought RSI of 72.7 After a 1-for-50 Reverse Split?

kalkine.ca report covering Picard Medical Inc. (PMI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 1d ago

What Explains the 3.41% Premarket Decline for Picard Medical (NYSEAMERICAN:PMI)?

Kalkine report covering Picard Medical Inc. (PMI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Johnson Fistel, PLLP Investigates Claims on Behalf of

GlobeNewswire report covering Picard Medical Inc. (PMI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

What Is Behind Picard Medical (NYSEAMERICAN:PMI) 7% Rebound?

kalkine.ca report covering Picard Medical Inc. (PMI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 1d ago

Is Picard Medical (NYSEAMERICAN:PMI) Overbought After a 12.87% Gain and an RSI of 74.6?

kalkine.ca report covering Picard Medical Inc. (PMI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 1d ago

Why Did Picard Medical (NYSEAMERICAN:PMI) Surge 13.96% on Monday? The Catalyst, the Fundamentals and What Comes Next

kalkine.ca report covering Picard Medical Inc. (PMI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Which of Alaunos Therapeutics (NASDAQ:TCRT), JBDI Holdings (NASDAQ:JBDI), Picard Medical (NYSEAMERICAN:PMI) or NetApp (NASDAQ:NTAP) Is the Most Overbought Name on Wednesday's Pre-Market List, With an RSI Above 75?

kalkine.ca report covering Picard Medical Inc. (PMI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PMI Bull vs. Bear Conversation Board — What's Your Call at $8.35?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PMI 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $8.76 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PMI (D • RQD 48/100) a Buy at $8.11?

Welcome to the PMI (Picard Medical Inc.) Roar Pit. Current RQD Composite is 48/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $6.41 (-21.0%)

Spot @ $8.11

Pump the brakes on PMI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PMI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Picard Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $9.25 (+14.1%)

Spot @ $8.11

PMI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PMI, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $8.11 (52-wk range $2.65 - $208.00), any beat on forward guidance forces shorts and underweight funds to chase.